PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links


Article published in Urologia Polska 1996/49/4.

authors

Andrzej Borkowski
Z Kliniki Urologii AM W Warszawie
Kierownik Kliniki: Prof. dr hab. A. Borkowski

keywords

prostate prostate cancer antiandrogens maximal androgen blockade ? Intermittent therapy

references

  1. [1] Abi-Aad, A. S. A.: Prostate cancer-treatment of disseminated disease. Acta Urol.
  2. Belgica (1996), 64, 2, 67.
  3. [2] Akakura, K., Bruchovsky, N., Goldenberg, S. L.: Effects of intermittent androgen
  4. Suppression on androgen-dependent tumors. Cancer (1993), 71,2782.
  5. [3] Bierkens, A. E, Debruyne, F.M.J.: Complete hormonal blockage - antiandrogens.
  6. Acta. Urol. Belgica (1996), 64, 2, 77.
  7. [4] Blackledge, G.: Casodex - mechanism of action and opportunities for usage. Can-
  8. cer (1993), 72, 3830.
  9. [5] Blumenstein, B.: Overview analysis issues using the combined androgen depriva-
  10. tion overview analysis as an example. Urol. Oncol.(1995), 1,95.
  11. [6] Boccon-Gibod, L., Fournier, G, Bottet, P, Marechal, J. M, Guiters, J., Rischmannn,
  12. E, Hubert, J., Soret, J. Y, Mangin, P, Mallo, C: Flutamide versus orchidectomy in
  13. patients with metastatic prostate carcinoma. Abstracts Xlth Congress of EUA.
  14. Berlin 1994. Abstr. 25.
  15. [7] Crawford, E. D, Eisenberger, M. A., McLoad, D. G., Don, F.A., Davis, A.: A control-
  16. led trial of leuprolide with and without flutamide in prostate carcinoma.
  17. N. Eng. J. Med. (1989), 321,419.
  18. [8] Crawford, E. D., De Antoni, E. P: Combined androgen blockade: an idea whose
  19. time is come. Proceedings of 4th Intern. Symposium on recent advances in urolo-
  20. gical cancer diagnosis and treatment. Paris 1994. S.C.I. ed. str. 262.
  21. [9] Denis, L. J., Carneiro deMoura, J. L., Bono, A., Sylvester, R., Whelan, P, Newling, D.,
  22. de Pauw, M.: Gosereline acetate and flutamide versus bilateral orchiectomy:
  23. A phase III EORTC trial (30853). Urology. (1993), 42,119.
  24. [10] Denis, L. J.: Adding antiandrogen to castration: Is the controversy resolved? Pro-
  25. ceedings of 4th Intern. Symposium on recent advances in urological cancer diagno-
  26. sis and treatment. Paris 1994 S.C.I. ed. str. 273.
  27. [11] Denis, L. J., Whelan, E, Caneiro de Moura, J. L., Newling, D. W., Bono, A., Sylwester,
  28. R. J., for the EORTC Genito-urinary Tract Cancer cooperative group.: Long term
  29. results of an EORTC phase III randomised trial (30853) Comparing orchidectomy
  30. to Zoladex plus flutamide in patients with metastatic prostate cancer. J. Urol.
  31. (1996), 155, 5, Abstr. 1064.
  32. [12] Denis, L. J.: Controversies surrounding hormonal deprivation. Acta Urol. Belgica
  33. (1996), 64, 2, 81.
  34. [13] Dijkman, G. A., Debuyne, E M. J., Janknegt, R. A., the Netherlands and the interna-
  35. tional Nitulamide study group.: Long-term efficacy and safety of nitulamide plus
  36. orchidectomy in advanced prostate cancer, and the significance of early PSA nor-
  37. malization. J. Urol. (1996), 155,5, Abstr. 1192.
  38. [14] Dupont, A., Gomez, J. L., Cusan, L., Koutsilieris, M., Labrie, E: Response to fluta-
  39. mide withdrawal in advanced prostate cancer in progression under Combination
  40. therapy. J. Urol. (1993), 150,908.
  41. [15] Goldenberg, S. L., Bruchovsky, K, Gleave, M. E., Sullivan, L. D.: Low-dose cyprote-
  42. rone acetate plus mini-dose diethylstilbestrol - a protocol for reversible medical
  43. castration. Urology. (1996), 47,882.
  44. [16] Janknegt, R. A., Abbou, C. C, Bartoletti, R., Bernstein-Hann, L, Bracken, B., Bris-
  45. set, J. M., Calais da Silva, E, Chisholm, G., Crawford, E. D., Debruyne, E M., Dijk-
  46. man, G. D., Frick, J., Goedhals, L., Kronagel, H., Venner, P. M.: Orchiectomy and
  47. nitulamide or placebo as treatment of metastatic prostate cancer in a multinational
  48. double-blind randomized trial. J. Urol. (1993), 149,77.
  49. [17] Kaisary, A. V: Current clinical studies with a new nonsteroidal antiandrogen,
  50. casodex. Prostate (1994), 5,27.
  51. [18] Kaisary, A. V, Tyrrell, C. J., Beacock, C, Lunglmayr, G, Debruyne, E, and Casodex
  52. study group: A randomized Comparison monotherapy with casodex 50 mg daily and
  53. castration in treatment of metastatic prostate carcinoma. Eur. Urol. (1995), 28,215.
  54. [19] Kelly, W. K, Scher, H. I.: Prostate specific antigen decline after antiandrogen
  55. withdrawal: the flutamide withdrawal syndrome. J. Urol. (1993), 149,607.
  56. [20] Labrie, E, Dupont, A., Belanger, A.: A new approach in the treatment of prostatic
  57. cancer. Complete instead of partial withdrawal of androgens. Prostate (1983), 4,579.
  58. [21] Labrie, E: Intracrinology: The basis for the rational design of prostate cancer ther-
  59. apy. Symposium on future prospects in the management of prostatic carcinoma.
  60. Barcelona 1993. Adelphi Communications Ltd. str. 62.
  61. [22] Mahler, C: Is disease flare a problem? Cancer. Suppl. (1993), 72,3799.
  62. [23] Mahler, C.: Antiandrogen as monotherapy. Proceedings of 4th Intern. Symposium
  63. on recent advances in urological cancer diagnosis and treatment. Paris 1994. S.C.I.
  64. ed, str.339.
  65. [24] McConnell, J.: Raport 9 Komitetu First International Consultation on Prostate
  66. Cancer. Monaco 20-22 June 1996 (w przygotowaniu).
  67. [25] Noldus, J., Ferrari, M., Prestigiacomo, A., Stamey, T. A.: Effect of flutamide and
  68. flutamide plus castration on prostate size in patients with previously untreated
  69. prostate cancer. Urology. (1996), 47,713.
  70. [26] Ornstein, D. K., Rao, G. S., Charton, G. T, Andriole, G. L.: Combined finasteride
  71. and flutamide therapy in men with advanced prostate cancer. J. Urol. (1996), 155,5,
  72. Abstr. 1070.
  73. [27] Pavone-Macaluso, M., De Voogt, H. i., Vigiano, G.: Comparison of diethystilbe-
  74. strol, cyproterone acetate and medroksyprogesterone acetate in the treatment of
  75. advanced prostate cancer. Final analysis of randomised phase III trial of the EORTC
  76. urological group. J. Urol. (1986), 136,624.
  77. [28] Prostate Cancer Trialists' collaborative group.: Maximal androgen blockade in
  78. advanced prostate cancer: an overview of 22 randomized trials with 3283 deaths in
  79. 5710 patients. Lancet (1995), 346,265.
  80. [29] Schellhammer, P. E: Combined androgen blockade for the treatment of metastatic
  81. cancer of the prostate. Urology (1996), 47,622.
  82. [30] Scher, H. I., Kelly, W K.: Flutamide withdrawal syndrome: its impact on clinical
  83. trials in hormone-refractory prostate cancer. J. Clin. Oncol. (1993), 11,1566.
  84. [31] Schroder, E H.: Cyproterone acetate-mechanism of action and clinical effective-
  85. ness in prostate cancer treatement. Cancer Suppl. (1993), 72,3810.
  86. [32] Soloway, M., Schelhammer, P? Rooholah, S., Block, N., Venner, P., Patterson, L.,
  87. Sarosdy, M., Yogelzang, M., Jones, J., Kolvenbag, G., for the Casodex Combination
  88. study group. J. Urol. (1996), 155,5, Abstr. 1193.
  89. [33] Studer, U. E., Schroder, F. H, Stockle, M., Brausi, M., Kurth K-H., Sarramon. J-P,
  90. Sylvester R., de Voogt H. and members of the EORTC GU-Group, Europę.: Long
  91. term results of a prospective randomised trial (EORTC 30843) Comparing LHRH
  92. treatment combined with either short term or long term antiandrogen treatement
  93. to orchidectomy. J. Urol. (1996), 155,5, Abstr. 1192.
  94. 34] Sylvester, R. I, Denis, L. I, de Voogt, H., for the EORTC Genito-urinary tract
  95. cancer cooperative group.: The importance of prognostic factors in the interpreta-
  96. tion of metastatic prostate cancer trials. J. Urol. (1996), 155,5, Abstr. 1190.
  97. [35] Trachtenberg, J.: Future approches to combined therapy in prostate cancer. Sym-
  98. posium on future prospects in the management of prostatic carcinoma. Adelphi
  99. Communications Ltd. Barcelona 1993, str. 85.
  100. [36] Tyrrell, C. J.: Casodex: a pure non-steroidal antiandrogen used as monotherapy in
  101. advanced prostate cancer. Prostate (suppl 4) (1992), 5,27.
  102. [37] Voogt, H. I, Rao, B. R., Geldof, A. A., Gooren, L. J. B., Bouman J. G.: Androgen
  103. action blocade does not results in reduction in size but changes histology of the
  104. normal human prostate. The Prostate (1987), 11,305.